Peanut Allergy Clinical Trial
— REVIALLOfficial title:
Visual Recognition of Allergens by Allergic Patients and/or Their Parents
Verified date | November 2016 |
Source | Lille Catholic University |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Observational |
Food allergies are constantly increasing. Peanut and nut allergies are a major cause of
allergic reactions. Diagnosed patients are also at risk, because 27% of the patients that
had an allergic reaction have another one in the following year with the same food, despite
a real improvement in industrial products labeling.
The investigators have observed in the allergy Unit that patients (and/or their family)
following an elimination diet, sometimes since several years, use very strict elimination
strategies. Those strategies sometimes lead to incapacities to recognize the allergens. Yet,
a good identification of the allergen is the key to a successful elimination and the
non-identification a known risk factor.
Ferdman shown in 2006 that 27% of the patients didn't recognize the allergen there were
allergic to. However, this is a US study, and geographical specificities have an impact on
food consumption and culture. Food allergology needs to take those two elements into
account. For example, in France, a single food can have two names. It is the case of peanut,
which can be called "arachide", or more frequently "cacahuète".
The goal of the study is to observe patient aptitudes to recognize peanut (and the
association between the two names) and other nuts available in France and define by the
European law, using a plate with various food samples in seed or in shell.
Thus, patients in care at the allergy Unit of Saint Vincent Hospital of Lille (France) and
their families were surveyed with a standardized procedure at the beginning of their
therapeutic education and their capacity to recognize various nuts, to identify peanut
("cacahuète" or "arachide") and to associate the two words "cacahuète" and "arachide" was
assessed. It is a standard procedure in therapeutic education, and the responses have been
systematically entered in the medical record.
The main objective of this study is to describe peanut or nut allergic patient capacity
(adult, children and/or the family) to visually identify the foods there are allergic to.
The secondary objective of this study is to describe the capacity of patient that describe
themselves as allergic to "arachide" to associate this word to the word "cacahuète".
Status | Completed |
Enrollment | 440 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 3 Years and older |
Eligibility |
Inclusion Criteria: - Peanut or nut allergy - Following an elimination diet since at least 3 months - Results obtained at the beginning of a therapeutic education started from 2013 to 2015 Exclusion Criteria: - Patients opposed to enter the study |
Observational Model: Case-Only, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lille Catholic University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patient that can visually identify the foods there are allergic to. | At inclusion | No | |
Secondary | number of patients presenting themselves as allergic to "arachide" knowing it is a synonym of "cacahuète" | at inclusion | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05667610 -
Immune-supportive Diet and Gut Permeability in Allergic Children
|
N/A | |
Recruiting |
NCT05440643 -
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
|
Phase 1 | |
Terminated |
NCT03849079 -
Validation of the HYPONUT Product
|
N/A | |
Completed |
NCT02979600 -
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
|
N/A | |
Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
Completed |
NCT01955109 -
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
|
Phase 2 | |
Recruiting |
NCT04415593 -
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
|
N/A | |
Active, not recruiting |
NCT04511494 -
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
|
N/A | |
Active, not recruiting |
NCT04887441 -
Allergology: Information, Data and Knowledge Organization
|
||
Active, not recruiting |
NCT04881773 -
Oral Low Doses Tolerance INduction Study for Peanuts
|
||
Completed |
NCT03682770 -
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
|
Phase 2 | |
Terminated |
NCT03703791 -
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02916446 -
Safety Study of Viaskin Peanut to Treat Peanut Allergy
|
Phase 3 | |
Active, not recruiting |
NCT02402231 -
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
|
Phase 2 | |
Completed |
NCT03337542 -
AR101 Real-World Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT05476497 -
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
|
Phase 1 | |
Completed |
NCT03648320 -
The Grown Up Peanut Immunotherapy Study
|
N/A | |
Completed |
NCT03292484 -
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
|
Phase 3 | |
Completed |
NCT03852342 -
Reactive Doses and Times During Oral Food Challenge to Peanut
|
||
Recruiting |
NCT05138757 -
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
|
Phase 1/Phase 2 |